Generic placeholder image

Current Medicinal Chemistry - Anti-Cancer Agents

Editor-in-Chief

ISSN (Print): 1568-0118
ISSN (Online): 1875-5968

Glucuronides in Anti-Cancer Therapy

Author(s): Xi Chen, Bingyuan Wu and Peng George Wang

Volume 3, Issue 2, 2003

Page: [139 - 150] Pages: 12

DOI: 10.2174/1568011033353470

Price: $65

Abstract

Glucuronide prodrugs have shown promising efficacy in anti-cancer therapy due to their increased specificity and reduced systemic toxicity. The prodrugs can be used in prodrug monotherapy (PMT), which is based on elevated tumor β-glucuronidase activity. β-Glucuronidase activates the low-toxic prodrugs into highly cytotoxic agents specifically in the tumor site. The specificity of the prodrugs can be further improved by combined use with monoclonal antibodies against tumor-specific antigens, namely antibody-directed enzyme prodrug therapy (ADEPT), and the potency of the prodrugs can be greatly enhanced with the incorporation of an appropriate radionuclide in the combined chemo- and radio-therapy of cancer (CCRTC) strategy. The prodrugs can also be utilized to modify liposomes for efficient delivery of anti-cancer drugs.

Keywords: glucuronides, anti cancer therapy, glucuronide prodrug, prodrug monotherapy, antibody directed enzyme prodrug therapy, combined chemo radiotherapy


Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy